Sharda Cropchem reported a 9% year-on-year revenue increase to ₹1,074 crore in Q1 FY27. EBITDA margins expanded to 16.6%, driven by strong performance in NAFTA and LATAM, despite a temporary slowdown in Europe. The company also improved its working capital cycle.
Sharda Cropchem Ltd. Q1 FY27 Financial Update
Revenue grew 9% year-on-year to ₹1,074 crore. EBITDA margin expanded by 220 basis points to 16.6%. Reader Takeaway: Margin expansion and regional diversification offer resilience, but currency volatility poses a risk. ## What just happened Sharda Cropchem reported a 9% rise in revenue for the first quarter of FY27, reaching ₹1,074 crore. This growth was primarily fueled by its operations in NAFTA and Latin America. The company also saw its EBITDA margin improve by 220 basis points to 16.6% and its gross margin expand by 120 basis points to 36.7%. Despite softer demand in Europe due to weather-related destocking by distributors, the company managed to maintain attractive margins in the region. Like-to-like Profit Before Tax (PBT) grew by 16% year-on-year, excluding forex gains. ## Why this matters The results demonstrate Sharda Cropchem's ability to navigate regional market challenges and achieve margin growth. The expansion in operational margins indicates improved efficiency and pricing power. Growth in key markets like NAFTA and LATAM signals diversification benefits, while the improvement in the working capital cycle to 88 days suggests better cash flow management. This resilience is crucial for investors monitoring the company's profitability and operational health. ## The backstory Sharda Cropchem operates with an asset-light business model, focusing on product registration and marketing. The company's performance is often influenced by global agrochemical demand, regulatory approvals, and currency fluctuations. Historically, its model has allowed for flexibility, but it also exposes the company to forex volatility and dependence on timely registrations. ## What changes now The company's focus will be on monitoring the normalization of demand in the European market and sustaining its growth momentum in NAFTA and LATAM. Management will also aim to achieve its long-term margin guidance of 18%-20%. The improved working capital efficiency should support smoother operations. ## Risks to watch Key risks include currency volatility, which can significantly impact reported profits. The company is also susceptible to regional weather patterns affecting European demand and distributor inventory levels. Furthermore, the timeline for obtaining new product registrations is subject to government approvals and involves inherent uncertainties. ## Peer comparison While specific peer data for Q1 FY27 is not detailed in the filing, Sharda Cropchem's performance in terms of revenue growth and margin expansion can be benchmarked against other agrochemical companies operating globally and in India. Its asset-light model differentiates it from integrated manufacturers. ## Context metrics (time-bound) * **Revenue:** ₹1,074 crore (Q1 FY27), a 9% year-on-year increase. * **EBITDA Margin:** 16.6% (Q1 FY27), up 220 basis points year-on-year. * **Gross Margin:** 36.7% (Q1 FY27), up 120 basis points year-on-year. * **Working Capital Cycle:** Improved to 88 days as of June 30, 2026, down 10 days from March 31, 2026. * **Total Product Registrations:** 3,016 as of June 30, 2026. * **Q1 Capex:** ₹273 crore, including one-off spending. ## What to track next Investors should closely watch the recovery of European market demand, the company's progress in securing new product registrations, and its ability to manage currency risks. Continued improvement in the working capital cycle and progress towards achieving long-term margin targets will also be key indicators.
